CRVS241220C2000
- 0.00
- 0.000.00%
Corvus Pharmaceuticals Newsroom
Here's Why We're Not At All Concerned With Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $14
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Falls After Early-stage Data for Eczema Therapy
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost
Express News | Corvus Pharmaceuticals Inc - Lowest Dose Level Cohorts Show Favorable Safety and Efficacy
Market-Moving News for December 18th
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Biggest Stock Movers Wednesday: COMM, HEI, and More
Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding
Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal
Express News | Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Individual Investors Account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Ownership, While Private Equity Firms Account for 16%
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity